Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Nurix Therapeutics ( (NRIX) ) has shared an update.
Nurix Therapeutics announced its key objectives for 2025, which include initiating clinical trials for NX-5948, expanding its development for additional cancer and inflammatory diseases, and advancing its portfolio of partnered programs in inflammation and immunology. The company’s achievements in 2024, including significant progress in clinical trials and regulatory advancements for NX-5948, position it for upcoming pivotal studies and further developments in its degrader-based treatment pipeline.
More about Nurix Therapeutics
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines, aimed at improving treatment options for patients with cancer and inflammatory diseases.
YTD Price Performance: -6.51%
Average Trading Volume: 909,629
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.29B
For a thorough assessment of NRIX stock, go to TipRanks’ Stock Analysis page.